eFFECTOR Therapeutics, Inc. (EFTR)
- Previous Close
1.8100 - Open
1.8399 - Bid 1.8500 x 100
- Ask 1.9300 x 400
- Day's Range
1.8300 - 1.9550 - 52 Week Range
1.6000 - 37.0000 - Volume
161,694 - Avg. Volume
379,290 - Market Cap (intraday)
6.969M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-16.3700 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
effector.comRecent News: EFTR
Performance Overview: EFTR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EFTR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EFTR
Valuation Measures
Market Cap
6.97M
Enterprise Value
9.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.28
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-85.26%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-35.81M
Diluted EPS (ttm)
-16.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
18.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-17.73M